Perjeta
Brand Name: Perjeta®
Composition: Pertuzumab (420mg 14ml concentrate for solution for infusion)
Product Description
Medical Info
Perjeta® is a targeted, prescription oncology medication containing pertuzumab, a recombinant humanized monoclonal antibody. It is specifically indicated for the treatment of HER2-positive breast cancer, often utilized in combination with trastuzumab and chemotherapy. Perjeta® works as a HER2 dimerization inhibitor; it uniquely binds to a distinct domain on the HER2 protein, preventing it from pairing with other HER receptors. This blockade effectively disrupts downstream cellular signaling pathways that drive tumor growth and cell survival. Administered as an intravenous infusion, it significantly helps slow disease progression and improves clinical outcomes for patients.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
